Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 20 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal CarcinomaNot yet recruitingNCT05898256Phase 1/2
- Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)RecruitingNCT05897268Phase 2
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingNCT05896839Phase 1/2
- Candonilimab (AK104) Plus Preoperative Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC)Not yet recruitingNCT05896787Phase 2
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLCRecruitingNCT05896059Phase 2
- Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver MetastasesNot yet recruitingNCT05894837Phase 2
- TQB2223 Injection in Combination With Penpulimab in Patients With Advanced CancersRecruitingNCT05894421Phase 1
- Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis (CASTLE-09)RecruitingNCT05893056Phase 2
- Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)RecruitingNCT05891821Phase 2
- Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 TrialNot yet recruitingNCT05891080Phase 2
- MEDI5752 in Patients With Mature Tertiary Lymphoid Structures Solid Tumors.Not yet recruitingNCT05888857Phase 2
- Effect of Nivolumab vs Placebo in Patients With Acute Myocardial Infarction: A Randomized Clinical TrialNot yet recruitingNCT05887830Phase 1/2
- HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 TrialRecruitingNCT05886465Phase 2
- The Efficacy and Safety of Penpulimab in the Treatment of Metastatic PPGL Patients Who Fail to Other Systemic TreatmentRecruitingNCT05885399Phase 2
- Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNot yet recruitingNCT05882630Phase 1/2
- TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II StudyRecruitingNCT05882370Phase 2
- Pembrolizumab and EV With Radiation Therapy for MIBC Patients (PEVRAD)RecruitingNCT05879653Phase 2
- Biomarkers in Immunotherapy of MelanomaRecruitingNCT05878977Not applicable
- Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced，High-Risk，MSS Rectal CancerRecruitingNCT05877573Not applicable
- Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)RecruitingNCT05872724Phase 2
- Perioperative Chemotherapy Combined With Serplulimab or Placebo for pMMR Locally Advanced Gastric Adenocarcinoma (FOCUS-05)RecruitingNCT05872685Phase 2
- A Combination Study of CAR-T Therapy in r/r B-NHLRecruitingNCT05871684Phase 2
- BPB-101 in Subjects With Metastatic or Locally Advanced Solid TumorsRecruitingNCT05869240Phase 1/2
- A Study of PM1022 in Patients With Advanced TumorsRecruitingNCT05867771Phase 1/2
- Clinical Study of PM1003 in Phase I/IIa Treatment of Advanced Malignant Solid TumorsRecruitingNCT05862831Phase 1/2
- Anlotinib Hydrochloride Capsules Combined With Penpulimab Injection for the Treatment of Hepatocellular Carcinoma at High Risk of Recurrence.RecruitingNCT05862337Phase 3
- A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyRecruitingNCT05862285Phase 3
- Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II TrialRecruitingNCT05862168Phase 2
- A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast CancerRecruitingNCT05862064Phase 3
- Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT05861557Phase 2
- Nivolumab in Combination With Chemotherapy for FGFR2-positive Metastatic Gastric CancerRecruitingNCT05859477Phase 2
- A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)Not yet recruitingNCT05859217Phase 2
- Total Neoadjuvant Therapy With Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Ultra Low Rectal AdenocarcinomaRecruitingNCT05858567Phase 2
- Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic TherapyRecruitingNCT05856864Phase 1
- PREventing Second Cancers With DOSTARlimabRecruitingNCT05855811Phase 2
- Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon CancerRecruitingNCT05855200Phase 3
- Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingNCT05853172Phase 2
- Pembrolizumab in High-risk Thyroid CancerRecruitingNCT05852223Phase 2
- Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)RecruitingNCT05845450Phase 2
- Total Neoadjuvant Therapy Combined With Tislelizumab for Local Advanced of Middle and Low Rectal CancerRecruitingNCT05845268Phase 2
- Sequential or Up-front Triple Treatment With Durvalumab, Tremelimumab and Bevacizumab for Non-resectable Hepatocellular Carcinoma (HCC) PatientsRecruitingNCT05844046Phase 2
- Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCCRecruitingNCT05842317Phase 1/2
- Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)Not yet recruitingNCT05842018Phase 2
- Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingNCT05841472Phase 2
- Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III Colorectal CancerNot yet recruitingNCT05841134Phase 2
- The Combination of Radiotherapy，Surufatinib and Sintilimab in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05839275Phase 1/2
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCRecruitingNCT05839197Phase 2
- Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant Therapy for HER2-positive High-risk Upper Tract Urothelial Carcinoma (UTUC)RecruitingNCT05837806Phase 2
- A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsRecruitingNCT05836324Phase 1
- Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free)RecruitingNCT05835245Phase 2
- Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell CarcinomaNot yet recruitingNCT05833971Phase 2
- Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic CancerRecruitingNCT05832892Phase 1/2
- First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)RecruitingNCT05832827Phase 2
- Envafolimab Combined With Abraxane and Cisplatinas as Neoadjuvant Treatment for Resectable Esophageal CancerNot yet recruitingNCT05828381Phase 2
- Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC PatientsRecruitingNCT05825443Phase 2
- Cadonilimab Plus Nab -Paclitaxel for Patients With Recurrent, or Metastatic Cervical Cancer Resistant to Immune Checkpoint InhibitorsNot yet recruitingNCT05824494Phase 2
- Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced CholangiocarcinomaRecruitingNCT05823311Phase 3
- Gemcitabine Plus S1 and Tislelizumab in the First Line Therapy of Advanced Biliary Tract CarcinomaNot yet recruitingNCT05822453Phase 2
- Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal CarcinomaNot yet recruitingNCT05821452Phase 2
- Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial CancerRecruitingNCT05819892Phase 1
- Cadonilimab Plus Anlotinib for R/M/P Cervical CancerRecruitingNCT05817214Phase 2
- Toripalimab Plus Radiotherapy for Elderly Esophageal Cancer Patients Treated With Non-chemotherapy StrategyRecruitingNCT05817201Phase 2/3
- XELOX Combined With Cadonilimab Versus XELOX as Neoadjuvant Treatment for Locally Advanced, pMMR Rectal CancerRecruitingNCT05815303Phase 2
- Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal CancerRecruitingNCT05815290Phase 2
- Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNot yet recruitingNCT05812534Phase 2
- Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract CancerRecruitingNCT05812430Phase 2
- Efficacy and Safety of SCAI of Bevacizumab Combined With IC of Tislelizumab in the Treatment of Recurrent Glioblastoma.Not yet recruitingNCT05811793Not applicable
- Immunotherapy and Radioembolisation for Metastatic Hepatocellular CarcinomaRecruitingNCT05809869Phase 2
- Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical TherapyNot yet recruitingNCT05803915Phase 2
- Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLCRecruitingNCT05800340Phase 2
- QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRCRecruitingNCT05799820Phase 2
- Study of Chemoradiotherapy With Envafolimab For The Treatment of Locally Advanced Cervical CancerNot yet recruitingNCT05799469Phase 2
- pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerRecruitingNCT05799144Phase 2
- A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical CancerRecruitingNCT05798819Phase 3
- Study of Induction PD-1 Blockade (Nivolumab) in Patients With Surgically Complete Resectable Mismatch Repair Deficient Endometrial Cancer (NIVEC)RecruitingNCT05795244Phase 2
- TRUDI: TDXD+Durva in HER2+/Low IBCRecruitingNCT05795101Phase 2
- Assess the Efficacy of Radiotherapy and Sequential Chemotherapy and AK104 Before TME Surgery for Local CRC（AK104-IIT-13）Not yet recruitingNCT05794750Phase 2
- A Study of SHR-1802 in Combination With Adebrelimab in Patients With Advanced Solid TumorsRecruitingNCT05794477Phase 1/2
- Immunotherapy After Radiotherapy in Elderly ESCCNot yet recruitingNCT05791136Phase 2
- Cadonilimab (AK104) in the Treatment of Nasopharyngeal CarcinomaRecruitingNCT05790200Phase 2
- Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
- Cadonilimab Monotherapy as Neoadjuvant Therapy for Resectable II-IIIA Squamous Cell Lung CancerNot yet recruitingNCT05784974Phase 2
- Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid TumorsRecruitingNCT05784688Phase 1/2
- A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell CarcinomaRecruitingNCT05783921Phase 1/2
- Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Biliary Tract Cancer （CASTLE-08）RecruitingNCT05781074Phase 2
- Cryoablation+Ipilimumab+Nivolumab in MelanomaRecruitingNCT05779423Phase 2
- Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung CancerRecruitingNCT05777603Phase 1
- Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial CancerRecruitingNCT05775471Phase 2
- The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue SarcomaRecruitingNCT05774275Phase 1/2
- Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingNCT05773079Phase 2
- Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant ChemotherapyRecruitingNCT05772208Phase 3
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (B)RecruitingNCT05771402Phase 2
- Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer PatientsRecruitingNCT05771181Phase 2
- DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) DispositionRecruitingNCT05770102Phase 2/3
- A Novel Combination Therapeutic Strategy Aiming to Functional Cure for Chronic Hepatitis B Virus Infection (Sustained HBsAg Loss) (A)RecruitingNCT05769816Phase 2
- A Study to Evaluate Serplulimab in Combination With Docetaxel +S-1 VS. Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage IIIc Gastric CancerRecruitingNCT05769725Phase 2
- Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence FactorsRecruitingNCT05768464Phase 2
- Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate CancerRecruitingNCT05766371Phase 2
- Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural MesotheliomaRecruitingNCT05765084Phase 1/2
- Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene MutationRecruitingNCT05761470Phase 2